KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.

Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern, Elizabeth A Griffiths, Kim-Hien Dao, Amer M Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary-Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N Keer, Guillermo Garcia-Manero

Br J Haematol 207(2) 432-444

PMID40524338
PMCIDPMC12378960
DOI10.1111/bjh.20203
发表日期2025-06-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

DNA methyltransferase inhibitors (DNMTis) are commonly used in treating chronic myelomonocytic leukaemia (CMML); however, data from prospective studies of DNMTis in CMML are limited. The present analysis evaluated the efficacy, safety and pharmacodynamics of the oral DNMTi decitabine/cedazuridine in the subset of patients with CMML from the phase 2 and 3 trials, which led to the approval of this agent for myelodysplastic syndromes and CMML in the United States and Canada. Potential prognostic factors also were analysed. In all, 34 patients with CMML were screened and 33 were treated. Most patients (76% [n = 25]) had myelodysplastic type-CMML and 77% (n = 24/31 with DNA available for sequencing) had intermediate-2 or high-risk disease noted by CMML-specific prognostic scoring systems. The overall response rate was 76%, with 21% (n = 7) of patients achieving a complete response. Nearly half of the 11 patients who were red blood cell-transfusion dependent at baseline (46%) attained transfusion independence for ≥12 weeks, which was associated with survival. Median overall and transformation-free survival were 35.7 and 28.3 months, respectively, and the safety profile was similar to that previously reported for decitabine. This analysis described the use of decitabine/cedazuridine in CMML from consecutive, prospective, randomised trials and illustrated a median survival of nearly 3 years.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

FIGURE 2

Kaplan–Meier curves for (A) overall survival (OS) and transformation‐free survival (TFS), and for (B) overall and (C) transformation‐free survival stratified by clinical/molecular chronic myelomonocytic leukaemia‐specific prognostic scoring system. CI, confidence interval; Int, intermediate; NE, not evaluable.

A

overall survival and transformation-free survival

FIGURE 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

FIGURE 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

transformation-free survival

FIGURE 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Patient disposition. BM, bone marrow; DEC, decitabine; DEC‐C, DEC‐cedazuridine; MD‐CMML, myelodysplastic‐chronic myelomonocytic leukaemia; MP‐CMML, myeloproliferative‐CMML; SC, stem cell.
非 KM Figure
FIGURE 3Distribution of (A) mutations of interest (variant allele frequency [VAF] >2%) in the study population and (B) VAF (mean + standard deviation); and (C) number of mutations/patient: N = 33. Figures on pie chart slices reflect percentages and numbers of patients, with numbers of mutations represented by colours of pie slices .
非 KM Figure
FIGURE 4Effect of oral decitabine–cedazuridine therapy on overall survival. Proportional hazards model analysis of maximum likelihood estimates. CI, confidence interval; CMML, chronic myelomonocytic leukaemia; CPSS, CMML‐specific prognostic scoring system; CPSS‐MOL, molecular CPSS; CR, complete response; HI, haematological improvement; mCR, marrow CR; MD, myelodysplastic; MP, myeloproliferative; RBC, red blood cell; TI, transfusion independent; WBC, white blood cell.
非 KM Figure